share_log

太龙药业(600222.SH):控股子公司北京新领先主要为客户提供临床前药学研究、临床CRO服务

Tailong Pharmaceutical (600222.SH): Beijing Xinling, a holding subsidiary, mainly provides customers with pre-clinical pharmaceutical research and clinical CRO services

Gelonghui Finance ·  Dec 12, 2023 04:22

Gelonghui, December 12|Tailong Pharmaceutical (600222.SH) said on the investor interactive platform that Beijing Xinling, a holding subsidiary of the company, mainly provides customers with pre-clinical pharmaceutical research and clinical CRO services, and has rich experience in R&D services in high-end generic drugs and innovative drugs in cardiovascular, anti-tumor, and digestive system treatment fields.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment